Gilead Sciences Inc (GILD)

[Beatcovid]

Revive Therapeutics: Analyst sees 'substantial upside potential' as key assets move towards clinic

5000%-10,000% upside on approval in 2020 for Bucillamine.

Near term Catalyst
1.FDA signs off on Phase 3 Trail for Bucillamine Covid-19 that should put the market valuation between 10-20x the current price. Phase 3 drugs are valued between 300 million and 1.1 Billion. Covid-19 FDA Phase 3 arguably is worth more. This would be the only drug if approved thats not a vaccine or anti viral and has the lowest side effects compared to anything else on the market. This can be a real game changer. Also the patient population Revive Therapeutics is mild to moderate which is the largest covid-19 Patient Population. Approval we should see high double digit dollars.

2. Canadian Trial for Covid-19 Bucillamine.


3. Asian Trials for Covid-19 Bucillamine.

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

https://www.globenewswire.com/news-release/2020/06/30/2055779/0/en/Revive-Therapeutics-Announces-Submission-of-Investigational-New-Drug-Application-IND-with-U-S-FDA-for-Phase-3-Confirmatory-Study-for-Bucillamine-in-COVID-19.html

NVAX Covid Phase 2 Vaccine 5.6 Billion dollar market cap 52 week range $4.00-$110.00. todays price $94.00

MRNA Covid Phase 2 Vaccine 28 Billion market cap $64.00

INO Phase 1 Vaccine $2:00-$34.00 52 week range $26.00 today

VXRT preclinical Drug 52 week range .25-$14.00 1 Billion dollar market cap

CYDY .26-$10.00 2.75 Billion Market cap Phase 2 Drug CV-19

RVVTF .19 36 Million dollar market cap
Nearing Phase 3Covid-19 Drug with low side effects.